160 related articles for article (PubMed ID: 36853404)
21. Small Cell Neuroendocrine Carcinoma of the Endometrium with Difficulty Identifying the Original Site in the Uterus.
Iida T; Muramatsu T; Kajiwara H; Kato N; Itoh H; Narayama T; Machida H; Ikeda M; Shida M; Hirasawa T; Mikami M
Tokai J Exp Clin Med; 2020 Dec; 45(4):156-161. PubMed ID: 33300584
[TBL] [Abstract][Full Text] [Related]
22. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
23. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression.
Dong L; Zhou Q; Zhang Z; Zhu Y; Duan T; Feng Y
J Obstet Gynaecol Res; 2012 Aug; 38(8):1077-85. PubMed ID: 22540333
[TBL] [Abstract][Full Text] [Related]
24. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
26. High levels of Nrf2 determine chemoresistance in type II endometrial cancer.
Jiang T; Chen N; Zhao F; Wang XJ; Kong B; Zheng W; Zhang DD
Cancer Res; 2010 Jul; 70(13):5486-96. PubMed ID: 20530669
[TBL] [Abstract][Full Text] [Related]
27. Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma.
Shibata K; Kikkawa F; Kondo C; Mizokami Y; Kajiyama H; Ino K; Nomura S; Mizutani S
Gynecol Oncol; 2004 Nov; 95(2):307-13. PubMed ID: 15491750
[TBL] [Abstract][Full Text] [Related]
28. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors.
Rice LW; Stone RL; Xu M; Galgano M; Stoler MH; Everett EN; Jazaeri AA
Am J Obstet Gynecol; 2006 Apr; 194(4):1119-26; discussion 1126-8. PubMed ID: 16580307
[TBL] [Abstract][Full Text] [Related]
29. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
30. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
Dedes KJ; Wetterskog D; Mendes-Pereira AM; Natrajan R; Lambros MB; Geyer FC; Vatcheva R; Savage K; Mackay A; Lord CJ; Ashworth A; Reis-Filho JS
Sci Transl Med; 2010 Oct; 2(53):53ra75. PubMed ID: 20944090
[TBL] [Abstract][Full Text] [Related]
31. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.
Forster MD; Dedes KJ; Sandhu S; Frentzas S; Kristeleit R; Ashworth A; Poole CJ; Weigelt B; Kaye SB; Molife LR
Nat Rev Clin Oncol; 2011 May; 8(5):302-6. PubMed ID: 21468130
[TBL] [Abstract][Full Text] [Related]
32. Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
Gockley AA; Kolin DL; Awtrey CS; Lindeman NI; Matulonis UA; Konstantinopoulos PA
Gynecol Oncol; 2018 Aug; 150(2):219-226. PubMed ID: 29937315
[TBL] [Abstract][Full Text] [Related]
33. Postchemotherapy Endometrioid to Gastrointestinal Histotype Shift in Recurrent Endometrial Carcinoma.
Arciuolo D; Travaglino A; Santoro A; Pedone Anchora L; Inzani F; Angelico G; D'Alessandris N; Scaglione G; Valente M; Raffone A; Fanfani F; Zannoni GF
Int J Gynecol Pathol; 2022 Nov; 41(6):583-587. PubMed ID: 36302189
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium.
Shaco-Levy R; Sharabi S; Benharroch D; Piura B; Sion-Vardy N
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):226-32. PubMed ID: 18295959
[TBL] [Abstract][Full Text] [Related]
35. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
[TBL] [Abstract][Full Text] [Related]
36. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
37. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Zaino RJ; Brady WE; Todd W; Leslie K; Fischer EG; Horowitz NS; Mannel RS; Walker JL; Ivanovic M; Duska LR
Int J Gynecol Pathol; 2014 Nov; 33(6):543-53. PubMed ID: 25272292
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes.
Multinu F; Garzon S; Weaver AL; McGree ME; Sartori E; Landoni F; Zola P; Dinoi G; Aletti G; Block MS; Gadducci A; Mariani A
Int J Gynecol Cancer; 2021 Apr; 31(4):537-544. PubMed ID: 33608453
[TBL] [Abstract][Full Text] [Related]
39. Endometrial carcinoma tumorigenesis and pharmacotherapy research.
Shu J; Fang S; Teichman PG; Xing L; Huang H
Minerva Endocrinol; 2012 Jun; 37(2):117-32. PubMed ID: 22691886
[TBL] [Abstract][Full Text] [Related]
40. Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.
Nishimura T; Nakamura K; Yamashita S; Ikeda S; Kigure K; Minegishi T
BMC Cancer; 2015 Dec; 15():957. PubMed ID: 26673416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
